Sign in to view content

PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.

Touka Banaee, MD

Video
Published 2019

Related

Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
One-Year Outcome of Intravitreal Ziv-Aflibercept Therapy For Nonresponsive Neovascular Age-Related Macular Degeneration
Jay Chhablani, MD
On Demand Cases, Courses, and Papers
2017
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021

Category: AMD-Neovascular

See more